Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.
Xiuning Le, MD, PhD, an assistant professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects (AEs) and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer (NSCLC).
According to Le, the observation was based on the results of cohort 5 of the phase 2 ZENITH20 clinical trial (NCT03318939), which was similar to the other 4 cohorts in terms of allowing patients with genetically-mutated NSCLC such as those with EGFR, or HER2 exon 20 mutations. However, instead of receiving the whole 16 mg of poziotinib at once, patients took an 8 mg pill twice daily.
The goal was to maintain or improve efficacy while managing the drug’s intrinsic AEs, most notably rash and diarrhea. Both of these AEs can impact a patient’s quality of life substantially, noted Le.
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
March 25th 2024During a Case-Based Roundtable® event, Christine, Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non–small cell lung cancer in the first article of a 2-part series.
Read More
Selection of First-Line NSCLC Therapy Influenced by Delayed Testing
March 8th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.
Read More